Aerie Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
March 21 2018 - 7:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma and other diseases of the eye,
today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief
Executive Officer, will present in a fireside chat discussion at
the 17th Annual Needham Healthcare Conference on Tuesday, March 27,
2018 at 4:00pm Eastern Time in New York, NY. Dr. Anido will provide
an Aerie overview and business update.
The fireside chat will be webcast live and may be accessed by
visiting Aerie's website at http://investors.aeriepharma.com/. A
replay of the webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with open-angle glaucoma
and other diseases of the eye. Aerie's first product, Rhopressa®
(netarsudil ophthalmic solution) 0.02%, for the reduction of
elevated intraocular pressure (IOP) in patients with open-angle
glaucoma or ocular hypertension, was approved by the U.S. Food
and Drug Administration (FDA) in December 2017. A link to
the full product label is available on the Aerie website at
http://investors.aeriepharma.com. Aerie’s advanced-stage product
candidate, Roclatan™ (netarsudil/latanoprost ophthalmic solution)
0.02%/0.005%, which is a fixed dosed combination of Rhopressa® and
widely prescribed PGA (prostaglandin analog) latanoprost, achieved
its primary efficacy endpoint in two Phase 3 registration trials,
named Mercury 1 and Mercury 2, and also achieved successful
12-month safety and efficacy results in Mercury 1. The Roclatan™
NDA submission is expected to take place in the second quarter of
2018. Aerie is also focused on global expansion and the development
of additional product candidates and technologies in
ophthalmology.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180321005033/en/
Aerie PharmaceuticalsMedia:Tad Heitmann,
949-526-8747theitmann@aeriepharma.comorInvestors:Richard Rubino
908-947-3540rrubino@aeriepharma.comorBurns McClellan, Inc., on
behalf of Aerie PharmaceuticalsMedia:Justin Jackson,
212-213-0006jjackson@burnsmc.comorInvestors:Ami Bavishi,
212-213-0006abavishi@burnsmc.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2023 to Apr 2024
